Phenylalanine

Phenylalanine

SCHEMBL4958693

N[C@@H](Cc1ccccc1)C(=O)O.O=[N+]([O-])O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.79
ALPI P09923 1/20 0.79
PKM P14618 1/20 0.79
PTGS1 P23219 1/20 0.79
XIAP P98170 1/20 0.79
SLC1A3 P43003 2/20 0.57
SLC1A2 P43004 2/20 0.57
SLC1A1 P43005 2/20 0.57
CPA1 P15085 6/20 0.56
SLC15A1 P46059 1/20 0.53
LTA4H P09960 1/20 0.50
GRIA2 P42262 1/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Phenylalanine SCHEMBL22440727 1.00 SLC7A5 (0.79) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL8118 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL16398197 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL15671104 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL8119 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL23159186 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL837632 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL385804 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL16398196 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL43671 0.89 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240819-B1 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2025-03-04 US claimed
US-12612370-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-04-28 US disclosed
US-12577210-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-03-17 US disclosed
US-12577209-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-03-17 US disclosed
US-12540119-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-02-03 US disclosed
US-12522568-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-01-13 US disclosed
US-12473261-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2025-11-18 US disclosed
US-12448357-B1 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2025-10-21 US disclosed
US-20250171406-A1 AMINO ACID COMPOSITIONS THERMOLIFE INTERNATIONAL, LLC 2025-05-29 US disclosed
US-20250163001-A1 AMINO ACID COMPOSITIONS THERMOLIFE INTERNATIONAL, LLC 2025-05-22 US disclosed
US-8546526-B2 Peptide or peptidomimetic compounds containing the Arg-Gly-Asp sequence: new class of diagnostic noninvasive tracers as suitable tools for integrin alpha v beta 3-targeted therapy and imaging; antiproliferation agents; angiogenesis inhibititors; antitumor agents; anticarcinogenic agents; kits ADVANCED ACCELERATOR APPLICATIONS (FR) 2013-10-01 US disclosed
EP-1934248-B1 SELECTIVE ALFAVBETA3 RECEPTOR PEPTIDE ANTAGONIST FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS ADVANCED ACCELERATOR APPLIC (FR) 2013-05-01 EP disclosed
US-20080213190-A1 Selective Alfavbetas Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications ADVANCED ACCELERATOR APPLICATIONS (FR) 2008-09-04 US disclosed
EP-1934248-A2 SELECTIVE ALFAVBETA3 RECEPTOR PEPTIDE ANTAGONIST FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS Del Gatto, Annarita (IT) 2008-06-25 EP disclosed
US-7329644-B2 Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours BRACCO IMAGING S.P.A. (IT) 2008-02-12 US disclosed
WO-2007042241-A2 SELECTIVE ALFAVBETA3 RECEPTOR PEPTIDE ANTAGONIST FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS DEL GATTO ANNARITA (IT) 2007-04-19 WO disclosed
EP-1390405-B1 PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE BRACCO IMAGING SPA (IT) 2007-01-24 EP disclosed
US-20040254339-A1 Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours BRACCO IMAGING S.P.A. (IT) 2004-12-16 US disclosed
EP-1390405-A2 PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE Bracco Imaging S.p.A. (IT) 2004-02-25 EP disclosed
WO-2002094873-A2 PREPARATION OF CHOLECYSTOKININ AGONISTS AND ANTAGONISTS, AND THEIR THERAPEUTIC AND DIAGNOSTIC USE BRACCO IMAGING S.P.A. (IT) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473261-B2 Amino acid compositions ASNS, GLUL, ARGLU1 SLC7A5 13/4885ALPI 3074/4885PKM 1493/4885
US-12612370-B2 Amino acid compositions TNNT2, NPR1, NOS2 SLC7A5 51/4885ALPI 3024/4885PKM 375/4885
US-12448357-B1 Amino acid compositions SLC6A15, SLC1A5, SLC6A19 SLC7A5 13/4885ALPI 1869/4885PKM 3048/4885
US-12540119-B2 Amino acid compositions NOS2, NOS1, NOS3 SLC7A5 26/4885ALPI 3397/4885PKM 176/4885
US-20040254339-A1 Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours CCKBR, CCKAR, GRPR SLC7A5 182/4885ALPI 1381/4885PKM 982/4885
US-12240819-B1 Amino acid compositions SLC10A2, SLC1A5, CPT1B SLC7A5 10/4885ALPI 365/4885PKM 545/4885
US-12577209-B2 Amino acid compositions ARG1, NOS1, NOS2 SLC7A5 27/4885ALPI 3602/4885PKM 304/4885
US-20250171406-A1 AMINO ACID COMPOSITIONS ASNS, GLUL, ARGLU1 SLC7A5 14/4885ALPI 3020/4885PKM 1566/4885
US-12577210-B2 Amino acid compositions NPR1, SLC1A5, SLC6A15 SLC7A5 14/4885ALPI 4622/4885PKM 305/4885
US-20080213190-A1 Selective Alfavbetas Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications ITGAV, ITGB3, ITGA2B SLC7A5 1049/4885ALPI 3141/4885PKM 3966/4885
US-20250163001-A1 AMINO ACID COMPOSITIONS ASNS, GLUL, ARGLU1 SLC7A5 13/4885ALPI 3074/4885PKM 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.